Cargando…

Clinicopathological Characteristics And EGFR-TKIs Efficacies In Lung Squamous Cell Carcinoma Patients Harboring An EGFR Sensitizing Mutation

OBJECTIVE: This study analyzed the relationship between the clinicopathological features and epidermal growth factor receptor (EGFR) mutation status of squamous cell lung cancer (SqCLC) patients. Mutation status was analyzed by comparing the amplification refractory mutation system-polymerase chain...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhou, Shaozhang, Wang, Huilin, Jiang, Wei, Yu, Qitao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6826177/ https://www.ncbi.nlm.nih.gov/pubmed/31802898 http://dx.doi.org/10.2147/OTT.S225760

Ejemplares similares

Pulmonary pleomorphic carcinoma: A case harboring EGFR mutation treated with EGFR‐TKIs
por: Masuda, Ken, et al.
Publicado: (2018)

Comparison of Different EGFR Gene Mutation Status in Patients with Metastatic Non-Small Lung Cancer After First-Line EGFR-TKIs Therapy and Analyzing Its Relationship with Efficacy and Prognosis
por: Yuan, Chengliang, et al.
Publicado: (2021)

Adjuvant EGFR TKIs in NSCLC harboring EGFR mutations: looking for a consensus way
por: Attili, Ilaria, et al.
Publicado: (2020)

Microwave ablation combined with EGFR-TKIs versus only EGFR-TKIs in advanced NSCLC patients with EGFR-sensitive mutations
por: Wei, Zhigang, et al.
Publicado: (2017)

Clinical efficacy of first-generation EGFR-TKIs in patients with advanced non-small-cell lung cancer harboring EGFR exon 20 mutations
por: Chen, Dan, et al.
Publicado: (2016)

Combination of EGFR-TKIs with chemotherapy versus chemotherapy or EGFR-TKIs alone in advanced NSCLC patients with EGFR mutation
por: Wen, Miaomiao, et al.
Publicado: (2018)

Successful Treatment of Combined Large Cell Neuroendocrine Carcinoma Harboring an EGFR Mutation with EGFR-TKIs plus Bevacizumab: A Case Report
por: Muto, Satoshi, et al.
Publicado: (2020)

Impact of the generation of EGFR‐TKIs administered as prior therapy on the efficacy of osimertinib in patients with non‐small cell lung cancer harboring EGFR T790M mutation
por: Miyashita, Yosuke, et al.
Publicado: (2020)

Combination therapy of first and third generation EGFR-TKIs for an advanced lung adenocarcinoma patient harboring EGFR mutations and amplification: a case report
por: Chen, Yongxing, et al.
Publicado: (2020)

The influence of tumor heterogeneity on sensitivity of EGFR-mutant lung adenocarcinoma cells to EGFR-TKIs
por: Sun, Li, et al.
Publicado: (2019)

Efficacy and safety of EGFR‑TKIs plus Shenqi Fuzheng injection for non-small cell lung cancer patients with EGFR-sensitive mutations
por: Wang, Jia-li, et al.
Publicado: (2022)

Treatment with immune checkpoint inhibitors after EGFR‐TKIs in EGFR ‐mutated lung cancer
por: Ito, Takashi, et al.
Publicado: (2021)

The content of mutant EGFR DNA correlates with response to EGFR-TKIs in lung adenocarcinoma patients with common EGFR mutations
por: Hung, Ming-Szu, et al.
Publicado: (2016)

Chinese Medicine Combined With EGFR-TKIs Prolongs Progression-Free Survival and Overall Survival of Non-small Cell Lung Cancer (NSCLC) Patients Harboring EGFR Mutations, Compared With the Use of TKIs Alone
por: Wang, Yujia, et al.
Publicado: (2021)

Evaluating the Efficacy of EGFR-TKIs Combined With Radiotherapy in Advanced Lung Adenocarcinoma Patients With EGFR Mutation: A Retrospective Study
por: Wang, Yuxiang, et al.
Publicado: (2022)

Efficacy Differences of First-line EGFR-TKIs Alone vs in Combination with Chemotherapy in Advanced Lung Adenocarcinoma Patients with Sensitive EGFR Mutation and Concomitant Non-EGFR Genetic Alterations
por: ZHANG, Guowei, et al.
Publicado: (2022)

First-Line EGFR-TKIs Treatment in Stage I Non-Small-Cell Lung Cancer Patients Harboring EGFR Gene Mutations with Postoperative Intrapulmonary Recurrence
por: Zhu, Zhouyu, et al.
Publicado: (2021)

Efficacy of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) in targeted therapy of lung squamous cell carcinoma patients with EGFR mutation: a pooled analysis
por: Zhuang, Jingqi, et al.
Publicado: (2017)

c-Src Increases the Sensitivity to TKIs in the EGFR-Mutant Lung Adenocarcinoma
por: Min, Weili, et al.
Publicado: (2021)

Analyzing EGFR mutations and their association with clinicopathological characteristics and prognosis of patients with lung adenocarcinoma
por: Zhou, Xiuzhi, et al.
Publicado: (2018)

Concurrent gene alterations with EGFR mutation and treatment efficacy of EGFR-TKIs in Chinese patients with non-small cell lung cancer
por: Hu, Wentao, et al.
Publicado: (2017)

Establishment of prognostic nomograms for predicting the progression free survival of EGFR‐sensitizing mutation, advanced lung cancer patients treated with EGFR‐TKIs
por: Du, Xinyang, et al.
Publicado: (2022)

BIM Gene Polymorphism Lowers the Efficacy of EGFR-TKIs in Advanced Nonsmall Cell Lung Cancer With Sensitive EGFR Mutations: A Systematic Review and Meta-Analysis
por: Huang, Wu Feng, et al.
Publicado: (2015)

The Predictive Values of Advanced Non-Small Cell Lung Cancer Patients Harboring Uncommon EGFR Mutations—The Mutation Patterns, Use of Different Generations of EGFR-TKIs, and Concurrent Genetic Alterations
por: Tan, Jiarong, et al.
Publicado: (2021)

Bisphosphonates enhance EGFR-TKIs efficacy in advanced NSCLC patients with EGFR activating mutation: A retrospective study
por: Huang, Chu-Ying, et al.
Publicado: (2015)

Dynamics of EGFR mutations in plasma recapitulates the clinical response to EGFR-TKIs in NSCLC patients
por: Xiong, Liwen, et al.
Publicado: (2017)

The effectiveness of EGFR-TKIs against brain metastases in EGFR mutation-positive non-small-cell lung cancer
por: Bai, Hao, et al.
Publicado: (2017)

Anlotinib can overcome acquired resistance to EGFR‐TKIs via FGFR1 signaling in non‐small cell lung cancer without harboring EGFR T790M mutation
por: Lian, Zengzhi, et al.
Publicado: (2020)

Including Total EGFR Staining in Scoring Improves EGFR Mutations Detection by Mutation-Specific Antibodies and EGFR TKIs Response Prediction
por: Wu, Shang-Gin, et al.
Publicado: (2011)

Outcomes of salvage lung resections in advanced EGFR ‐mutant lung adenocarcinomas under EGFR TKIs
por: Chen, Ying‐Yuan, et al.
Publicado: (2021)

EGFR-TKIs resistance via EGFR-independent signaling pathways
por: Liu, Qian, et al.
Publicado: (2018)

Identification of genetic alterations associated with primary resistance to EGFR-TKIs in advanced non-small-cell lung cancer patients with EGFR sensitive mutations
por: Wang, Fang, et al.
Publicado: (2019)

The impact of adjuvant EGFR-TKIs and 14-gene molecular assay on stage I non–small cell lung cancer with sensitive EGFR mutations
por: Jiang, Yu, et al.
Publicado: (2023)

Phosphorylated STYK1 restrains the inhibitory role of EGFR in autophagy initiation and EGFR-TKIs sensitivity
por: Zhou, Cefan, et al.
Publicado: (2022)

Efficacy observation and prognosis analysis of EGFR-TKIs alone versus EGFR-TKIs plus chemotherapy in advanced lung adenocarcinoma with EGFR Exon 19 Deletion, Exon 21 L858R mutation: A historical cohort study
por: Zhou, Jinhua, et al.
Publicado: (2023)

Risk factors of brain metastasis during the course of EGFR-TKIs therapy for patients with EGFR-mutated advanced lung adenocarcinoma
por: Ma, Xiaoyan, et al.
Publicado: (2016)

Osimertinib or EGFR-TKIs/chemotherapy in patients with EGFR-mutated advanced nonsmall cell lung cancer: A meta-analysis
por: Huang, Lei, et al.
Publicado: (2019)

EGFR ‐plasma mutations in prognosis for non‐small cell lung cancer treated with EGFR TKIs: A meta‐analysis
por: Phan, Thang Thanh, et al.
Publicado: (2021)

A meta-analysis of adjuvant EGFR-TKIs for patients with EGFR mutation of resected non-small cell lung cancer
por: Cui, Ran, et al.
Publicado: (2022)

Case Report: Opportunities and Challenges of Immunotherapy in Heavily-Treated EGFR-Mutant Advanced Squamous Cell Lung Carcinoma After Progression on EGFR-TKIs and Chemotherapy
por: Jin, Wei, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_quu244chvgosq8u689jv4enfc5